Abstract
The French experts present at the Eutherapy Symposium held in Prague confirmed the importance of left ventricular hypertrophy (LVH) and microalbuminuria as major independent risk factors for cardiovascular disease. Factors that must be considered for the treatment of hypertension in patients, particularly with type 2 diabetes. Professor J.M. Mallion stressed the contribution of thiazide and thiazide-like diruetics as indapamid, especially the 1.5 mg SR formulation. Professor F. Forette and Doctor O. Hanon recalled that the HYVET study is expected to confirm the beneficial effect of this same treatment on morbidity and mortality in very elderly patients. Professor O. Dubourg recalled the beneficial effect of indapamid SR on LVH demonstrated in the LIVE study. Likewise, Professor M. Marre emphasized its important impact on microalbuminuria as shown in the NESTOR study.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Adult
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Albuminuria / complications
-
Albuminuria / drug therapy*
-
Albuminuria / prevention & control
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antihypertensive Agents / administration & dosage
-
Antihypertensive Agents / therapeutic use*
-
Benzothiadiazines
-
Cardiovascular Diseases / etiology
-
Delayed-Action Preparations
-
Diabetes Mellitus, Type 2 / complications*
-
Diuretics / administration & dosage
-
Diuretics / therapeutic use*
-
Double-Blind Method
-
Echocardiography
-
Electrocardiography
-
Enalapril / administration & dosage
-
Enalapril / therapeutic use
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Hypertrophy, Left Ventricular / complications
-
Hypertrophy, Left Ventricular / diagnosis
-
Hypertrophy, Left Ventricular / drug therapy*
-
Indapamide / administration & dosage
-
Indapamide / therapeutic use*
-
Meta-Analysis as Topic
-
Middle Aged
-
Multicenter Studies as Topic
-
Prognosis
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Sodium Chloride Symporter Inhibitors / administration & dosage
-
Sodium Chloride Symporter Inhibitors / therapeutic use
-
Time Factors
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Benzothiadiazines
-
Delayed-Action Preparations
-
Diuretics
-
Sodium Chloride Symporter Inhibitors
-
Enalapril
-
Indapamide